医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Centre for Commercialization of Regenerative Medicine Australia and BioCurate Enter Into a Memorandum of Understanding (MoU) to Accelerate the Translation of Therapies in the Australian Regenerative Medicine Sector

2019年06月29日 AM12:20
このエントリーをはてなブックマークに追加


 

MELBOURNE, Australia

The Centre for Commercialization of Regenerative Medicine Australia (CCRM Australia) is proud to collaborate with BioCurate to advance the translation and commercialisation of life changing therapies in the Australian regenerative medicine sector.

This MoU lays the foundation for collaboration between CCRM Australia and BioCurate. The scope promotes identification of suitable projects that parties can contribute towards by leveraging their expertise, networks and financial resources with the goal of joint translation of regenerative medicine. Where appropriate, both CCRM Australia and BioCurate will support each other’s programmes to train the next wave of entrepreneurs on the business of regenerative medicine.

The signing of the MoU brings together leaders in drug, biologic, regenerative medicine and medical technology development to pave a viable translation and commercialisation pathway for the Australian regenerative medicine sector.

About CCRM Australia

CCRM Australia is an Australian not-for-profit organisation supporting the development of foundational technologies to accelerate the commercialisation of regenerative medicine products and therapies. CCRM Australia’s focus is to bridge the commercialisation gap through a network of scientists, entrepreneurs, academic institutions and industry partners and address bottlenecks in the industry. CCRM Australia is modelled on the highly successful CCRM in Canada and is legally separate to CCRM. As a member of the Global CCRM network, CCRM Australia is a partner to a leading-edge industry consortium. CCRM Australia is supported by MTPConnect and the Victorian State Government.

Twitter: @CCRM_au
LinkedIn: https://www.linkedin.com/company/ccrm-australia/

About BioCurate

BioCurate Pty Ltd was formed jointly in June 2016 by The University of Melbourne and Monash University, with support from the Victorian State Government to accelerate early phases of new drug development. BioCurate is seeking to address the key challenges in early stage drug development and to increase the number, quality and rate of translation of new drug discoveries into medically sound projects that are attractive for investment via commercial or public-good routes. The Company’s vision is to be a recognized global leader in the translation of basic medical research into human therapeutics. For more information, please visit http://www.biocurate.com.

Twitter: @biocurate
LinkedIn: https://www.linkedin.com/company/biocurate/

View source version on businesswire.com: https://www.businesswire.com/news/home/20190628005383/en/

CONTACT

For more information:

CCRM Australia: Dr Chih Wei Teng chihwei.teng@ccrmaustralia.com.au

BioCurate: Dr Damien Bates d.bates@biocurate.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Apros Therapeutics Announces IND Clearance from U.S. FDA to Initiate the Trial of APR003, an Orally-Administered Gastrointestinal/Liver-Targeted TLR7 Agonist for Treatment of Advanced Colorectal Cancer (CRC) with Malignant Liver Lesions
  • Taiwan Innotech Expo (TIE) Showcases Strong Ecosystems in the Post-Pandemic World
  • Dr. Reddy’s Laboratories announces the launch of Over-The-Counter Diclofenac Sodium Topical Gel 1%, the store brand version of Voltaren® Arthritis Pain in the U.S. Market
  • GC Pharma Taps Small Molecule AI Expert Atomwise to Expand Hemophilia Franchise
  • 随着越来越多的客户和合作伙伴使用Denodo冠状病毒数据门户计划来对抗和最小化COVID-19的影响,其采纳率在不断提高